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Abstract: Since depression impacts all body systems, antidepressant treatments should relieve 
both the emotional and physical symptoms of depression. Duloxetine demonstrated antidepressant 
efﬁ  cacy at a dose of 60 mg qd in two placebo-controlled, randomized, double-blind studies and 
signiﬁ  cantly improved remission rates compared with placebo. Duloxetine-treated patients had 
signiﬁ  cant reduction in severity of the symptoms of depression as assessed by the HAM-D17, 
anxious symptoms as measured by the HAM-A and quality of life measures compared to placebo. 
Duloxetine also improved somatic symptoms, particularly painful symptoms which may have 
contributed to signiﬁ  cantly improved remission rates compared to placebo. Approximately 10% 
of the 1139 patients with major depressive disorder in placebo-controlled trials discontinued 
treatment due to an adverse event, compared to 4% of the 777 patients receiving placebo. In 
addition to nausea (1.4% incidence), which was the most common reason for discontinua-
tion, dizziness, somnolence, and fatigue were the most common AEs reported as reasons for 
discontinuation and all were considered drug-related. Duloxetine treatment lacks effects on 
ECG, increases heart rate, and has little effect on blood pressure or weight.
Keywords: duloxetine, depression, antidepressant, SNRI, quality of life, pain.
Introduction
Clinical presentation of major depressive disorder (MDD)
Depression is associated with both signiﬁ  cant functional impairment with work loss, 
impaired quality of life, and increased use of health care (Wells et al 1989; Hays et al 
1995; Bosc 2000; Herrman et al 2002; Simon et al 2002;). Depression is a common, 
generally chronic, and debilitating psychiatric condition. It is increasingly recognized 
that depression affects the entire body including painful physical symptoms that may 
be part of a broader cluster of symptoms that constitute major depressive disorder 
(Detke et al 2002a, b), not merely emotional symptoms (mood and anxiety). Physical 
symptoms, including sleep disruption, fatigue, pain and discomfort, and appetite dis-
turbance, are present in up to 80% of depressed patients (Gerber et al 1992). Physical 
symptoms occur in nearly all body systems and are often the presenting features in the 
non-psychiatric setting. Jackson et al (2001) found that ﬁ  ve or more physical symptoms 
are a signiﬁ  cant predictor of MDD in medical outpatients, with an odds ratio of 4.0. 
Furthermore, as evidence of their importance, physical symptoms, such as back pain 
and chest pain, predict greater severity of depression (Gerber et al 1992). Painful 
physical symptoms are highly prevalent among patients with depression (Simon and 
Von Korff 1991; Kroenke and Price 1993; Von Korff and Simon 1996; Gureje et al 
1997; Gureje et al 1998; Simon et al 1999).
The DSM-IV (APA 1994) deﬁ  nes “major depressive episode” by a cluster of symp-
toms, including somatic symptoms, representing a change from previous functioning 
and which must be present for at least 2 weeks. This cluster includes either 1) depressed Neuropsychiatric Disease and Treatment 2007:3(2) 194
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mood or 2) loss of interest or pleasure, and ﬁ  ve of nine 
depressive symptoms – depressed mood; anhedonia; appetite 
or weight change; sleep difﬁ    culties; psychomotor agitation 
or retardation; fatigue or decreased energy; concentration 
difﬁ  culties; feelings of worthlessness or guilt; and recurrent 
thoughts of death or suicide. Increasing awareness of the 
association between depression and physical symptoms is 
reﬂ  ected in the DSM-IV Text Revision (APA 2000), which 
describes associated features of major depressive episodes 
including “complaints of pain (eg, headaches or joint, 
abdominal, or other pains).”
The prospective naturalistic trial investigating response 
to SSRI therapy in primary care (the ARTIST study) (Corey-
Lisle et al 2004) indicated that most patients continue to have 
symptoms and impaired role functioning despite treatment 
(Klerman and Weissman 1992; Cronkite 1998; Corey-Lisle 
et al 2004). In that study, of the 601 patients randomized to 
treatment with 6 months of continuous therapy of therapeutic 
dose of paroxetine, ﬂ  uoxetine, or sertraline, 46% failed to 
meet the response criteria of a 50% reduction in their System 
Checklist (SCL-20) score. In addition, physical symptoms, 
especially painful symptoms, improved less than emotional 
symptoms. Unfortunately, in clinical practice, many patients 
receive inadequate dose strength or treatment duration 
(Keller et al 1986; Hirschfeld et al 1997), further reducing 
the effectiveness of treatment. Patients who achieve only 
partial response to treatment of a depressive episode (partial 
recovery) are more likely to have subsequent episodes.
Many patients who fully recover from a depressive 
episode eventually relapse, and each subsequent relapse may 
heighten the risk of a chronic, non-remitting course (Belsher 
and Costello 1988). The number of prior episodes predicts the 
likelihood of having subsequent episodes. It has been found 
that at least 60% of patients have a second episode after their 
initial episode; after two episodes patients have a 70% chance 
of having a third episode; and after three episodes, patients 
have a 90% chance of having a fourth episode (Cohen et al 
2004). In a 16-year follow-up of depressed inpatients, 50% 
showed either a chronic course or a series of relapses leading 
to a chronic course. As a consequence, the recommended 
duration of treatment and maintenance has been extended 
proportionately with the number and chronicity of prior 
depressive episodes (Kupfer et al 1992).
Other aspects associated with poorer outcome and/or 
disease persistence include dysthymic disorder, marked 
severity of the initial episode, and the presence of some 
chronic general medical conditions (eg, diabetes) (Swindle 
et al 1998), physical symptoms, and pain. In a study of 
patients given selective serotonin reuptake inhibitor (SSRI) 
therapy, physical symptoms were less likely to improve than 
emotional symptoms, well-being, and work/social function 
(Greco et al 2004). Increased prevalence rates of depression 
are found among patients with neurologic (23%) and cardio-
vascular disease (20%–27%), cancer (25%–42%), diabetes 
(8.5%–27.3%), and HIV (5.6%–12.2%) (Sutor et al 1998). 
The presence of major diagnosed medical conditions is a risk 
factor for a chronic course of depression over 4 years from 
the initiation of treatment (Swindle et al 1998).
Simon et al (1999) performed an analysis of 1146 subjects 
with major depression from a WHO screening survey of 
25,916 primary care patients in 14 countries. Approximately 
50% of those with major depression also reported at least 
three unexplained physical symptoms. In addition, the num-
ber of unexplained physical symptoms was more than three 
times higher in those with major depression (4.4 ± 4.2) than 
in those without major depression (1.2 ± 1.9).
Etiology of MDD
Because depression impacts all body systems (Kroenke and 
Price 1993; Posse and Hallstrom 1998), it is no surprise 
that investigations attempting to determine the effects of 
depression on hormones, neurotransmission, brain imaging, 
sleep architecture, immune function, and so on, have tended 
to identify differences between depressed patients and nor-
mal subjects. However, many of these investigations have 
not been replicated, or show signiﬁ  cant overlap between 
depressed and non-depressed groups leading to subsequent 
investigations of subgroups. Such investigations are further 
complicated by the temporal adaptation that occurs in many 
biological systems, resulting in differing effects after acute 
and chronic stress (Goldstein and Potter 2004).
Numerous biochemical mediators have been identified 
as potential factors related to the development of depression 
(Goldstein and Potter 2004). Among the best characterized neu-
rotransmitters involved in depression are serotonin (5-HT) and 
norepinephrine (NE) (Tran et al 2003). Enhancing both 5-HT and 
NE neurotransmission simultaneously may provide greater ef-
ﬁ  cacy and faster onset of action than enhancing either mechanism 
alone (Danish University Antidepressant Group 1986, 1990; 
Nelson et al 1991; Tran et al 2003). Descending 5-HT and NE 
pathways normally help to suppress pain inputs even when they 
cause minor discomfort. However, when these neurotransmitter 
systems malfunction, deﬁ  cient inhibition from the descending 
pathways may allow routine sensory input to be interpreted as Neuropsychiatric Disease and Treatment 2007:3(2) 195
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painful physical symptoms. Increasing neurotransmission of both 
5-HT and NE may offer greater antidepressant efﬁ  cacy when 
compared with potentiation of a single neurotransmitter (Nelson 
1998), and may be of clinical utility in the alleviation of painful 
physical symptoms associated with depression.
Epidemiology and relevant risk factors 
of MDD
Lifetime prevalence estimates for depression vary across 
studies, perhaps as a result of differences among instruments 
and survey methods used to identify the disorder. It is esti-
mated that the lifetime risk for MDD ranges from 10% to 
25% for women and from 5% to 12% for men.
The National Comorbidity Survey Replication (NCS-R), 
conducted with a nationally representative United States 
sample between 2001 and 2002, supported earlier ﬁ  nd-
ings from its predecessor, the National Comorbidity Study 
(Kessler et al 1994, 1996, 1997). It conﬁ  rmed that MDD is 
the single most prevalent psychiatric disorder (Kessler et al 
2003). Lifetime prevalence was 16.2%, with 6.6% of the 
population experiencing an episode in a 12-month period. 
Lifetime prevalence was greater among women than men and 
greater among Caucasians than non-Hispanic African-Ameri-
cans. In addition, lifetime depression was more common 
among homemakers (12 month only), the previously married 
(lifetime only), those with less than 12 years of education, 
and those living in or near poverty. Age of onset tended to 
rise rapidly from the late teens, with the suggestion that onset 
rates were earlier for more recent birth cohorts.
Lifetime MDD was comorbid with another psychiatric 
disorder in nearly 75% of respondents. The most common 
lifetime comorbid conditions were: anxiety (59%), impulse 
control disorder (30%), and substance use disorder (24%). 
MDD was associated with role impairment for nearly all re-
spondents (96.9%) with 12-month MDD. Impairment tended 
to be most severe in the social role domain (43.4% severe 
or very severe) and least in the work role domain (28.1% 
severe or very severe). Despite work being the least impaired 
domain, respondents with 12-month MDD reported a mean of 
35.2 days in the past year in which they were totally unable 
to work or perform usual activities. Regardless of prevalence 
estimates, most researchers agree that major depression is 
under-diagnosed and under-treated (Hirschfeld et al 1997).
Approaches to MDD treatment
According to published practice guidelines, the three 
primary treatment modalities for major depression are 
pharmacotherapy, psychotherapy, and their combination 
(Schulberg et al 1999; APA 2000). Selection of an initial 
treatment for acute depression is based on several factors 
including severity of symptoms, physiological and psychiatric 
comor  bidities, subtype of depression, and patient preference. 
Both pharmacotherapy and psychotherapy are also recom-
mended for continuation treatment (ie, 16–20 weeks follow-
ing remission) and maintenance treatment to prevent further 
recurrences of depressive episodes (APA 2000). A recent 
meta-analysis of randomized, controlled, double-blind clinical 
trials for MDD found that antidepressants and psychotherapy 
were both more effective than control conditions (Casacalenda 
et al 2002). The literature is inconsistent about whether phar-
macotherapy and psychotherapy in combination are superior 
to either treatment modality alone (see Table 1).
Numerous clinical trials have assessed the efﬁ  cacy of 
antidepressants, generally indicating that antidepressant treat-
ment of major depression is superior to placebo treatment 
(Dunbar et al 1993; Ellingrod and Perry 1995; Ballenger 
1996; Croft et al 1999; Feighner and Overo 1999; Gorman 
1999). The majority of studies that compare multiple anti-
depressants including SSRIs and tricyclic antidepressants 
(TCAs) show no signiﬁ  cant efﬁ  cacy differences between 
them (Holliday and Plosker 1993; Bennie et al 1995; Patris 
et al 1996; Sechter et al 1999; Stahl 2000; Kroenke et al 
2001), but with very high sample size or with meta-analysis 
using data from multiple studies, TCAs and dual reuptake 
inhibitors show greater efﬁ  cacy than SSRIs (Thase 2002). 
The core difference between the TCAs and SSRIs lies in 
safety proﬁ  les and tolerability. SSRIs lack the potentially 
serious side-effects of TCAs such as orthostatic hypotension, 
anticholinergic effects, and cardiac arrhythmia (Peretti et al 
2000). SSRIs are also non-toxic in overdose (Mason et al 
2000; Peretti et al 2000), their titration tends to be much sim-
pler, and patient dropout rates are lower (Mulrow et al 2000). 
Dual reuptake inhibitors, such as duloxetine, can maintain 
the safety and tolerability advantages of the SSRIs.
In the past, clinicians strived for patients to “feel better” 
(achieve antidepressant “response”); however, the goal has 
shifted to getting patients “well” or “virtually symptom 
free” (“remission”) because patients who experience only 
partial response to treatment of a depressive episode have 
a greater likelihood of developing subsequent episodes and 
of continuing to experience only partial recovery between 
episodes. Remission is ordinarily measured in clinical trials 
by achievement of a Hamilton Depression Rating Scale 
(HAM-D) score of 7 (Keller 2003).Neuropsychiatric Disease and Treatment 2007:3(2) 196
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Duloxetine, (+)-(S)-N-methyl-γ-(1-naphthyloxy)-2-thiophe-
nepropylamine hydrochloride, is a potent inhibitor of both 
5-HT and NE reuptake, possesses comparable afﬁ  nities in 
binding to NE and 5-HT transport sites, and has no signiﬁ  cant 
afﬁ  nity for cholinergic, histaminergic, dopaminergic, opioid, 
glutamate, GABA, cholinergic and adrenergic receptors in 
vitro (Bymaster et al 2001) and does not inhibit monoamine 
oxidase. Duloxetine undergoes extensive metabolism, but the 
major circulating metabolites have not been shown to con-
tribute signiﬁ  cantly to its pharmacologic activity. Preclinical 
studies have shown that duloxetine is a potent inhibitor of 
neuronal 5-HT and NE reuptake and a less potent inhibitor 
of dopamine reuptake.
Although the exact mechanisms of the antidepressant 
and central pain inhibitory action of duloxetine in humans 
are unknown, the antidepressant and pain inhibitory ac-
tions are believed to be related to its potentiation of 5-HT 
and NE activity in the central nervous system (CNS) 
(see Pharmacokinetics).
Pharmacokinetics and metabolism
Early duloxetine development was performed using a different 
formulation and lower dosage (Berk et al 1997). After failing 
to differentiate from placebo in depression Phase II/III trials, 
duloxetine was further evaluated and the present formulation 
and higher dosages were studied, beginning with new Phase I 
studies (Table 2). The absorption, distribution, metabolism, 
and elimination of duloxetine are presented in Table 3 (Lantz 
et al 2003; Skinner et al 2003, 2004; Eli Lilly and Co 2004; 
Suri et al 2005; Thase et al 2005; Anonymous 2006).
Efﬁ  cacy
Duloxetine trials
The efficacy of duloxetine for the acute treatment of 
major depressive disorder (MDD) was established in eight 
double-blind, randomized, placebo-controlled studies in 
adult outpatients who met DSM-IV (APA 1994) criteria 
for major depression (see Table 3 for study details). In the 
placebo-controlled MDD efﬁ  cacy trials duloxetine was con-
sistently signiﬁ  cantly more effective than placebo at doses 
60 mg/day.
Studies 1 and 2 were designed to test proof of concept in 
two underpowered trials in which one trial (Goldstein et al 
2002) showed superiority of duloxetine over placebo. Both 
of these studies used markedly under-powered ﬂ  uoxetine 
comparator treatment arms.
Studies 3 and 4 investigated a low and intermediate 
dose of duloxetine. In Study 3 paroxetine treatment was 
superior to placebo treatment, but duloxetine was not. In 
Study 4 (Goldstein et al 2004b), duloxetine treatment at 
both dosages was superior to placebo treatment, whereas 
paroxetine was not. Although the duloxetine vs parox-
etine comparison was not intended in these trials, Study 4 
showed duloxetine at 40 mg bid was superior to paroxetine 
20 mg which performed poorly in this trial. If these trials 
Table 1 Treatments for major depressive disorder
   Examples
Psychotherapy Cognitive-Behavioral  (CBT)
  Interpersonal psychotherapy (IPT)
Pharmacotherapy  SSRIs  Fluoxetine, paroxetine, sertraline 
  Tricyclics  Amitriptylline, nortriptyline, trazodone, 
 SNRI  Venlafaxine
 DNRI  Bupropion
  Non-traditional  St. John’s wort (Gaster and Holroyd 2000; 
    Williams et al 2000)
Other therapies  Exercise (Penninx et al 2002) 
  Electro-convulsive therapy (ECT) (Weiner and Coffey 1993) 
 Acupuncture
  Vagus nerve stimulation (VNS) - electrical stimulation of the left 
  vagus nerve in the neck via anterior chest wall- implanted 
 stimulator   
  Psychosurgery - surgical intervention to sever nerve ﬁ  bers 
  in the brain 
  Transcranial magnetic stimulation (r-TMS) - stimulation of local 
  electrical currents in the brain via a strong magnetic ﬁ  eld 
  created by a stimulating coil 
Abbreviations: DNRI, dopamine-norepinephrine reuptake inhibitor; SNRI,  serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.Neuropsychiatric Disease and Treatment 2007:3(2) 197
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S
k
i
n
n
e
r
 
e
t
 
a
l
 
2
0
0
4
)
 
N
o
 
d
i
f
f
e
r
e
n
c
e
 
i
n
 
C
m
a
x
 
b
e
t
w
e
e
n
 
h
e
a
l
t
h
y
 
e
l
d
e
r
l
y
 
f
e
m
a
l
e
s
 
(
6
5
–
7
7
 
y
e
a
r
s
)
 
a
n
d
 
h
e
a
l
t
h
y
 
m
i
d
d
l
e
-
a
g
e
 
 
 
f
e
m
a
l
e
s
 
(
3
2
–
5
0
 
y
e
a
r
s
)
,
 
b
u
t
 
A
U
C
 
2
5
%
 
h
i
g
h
e
r
 
a
n
d
 
h
a
l
f
-
l
i
f
e
 
o
f
 
a
b
o
u
t
 
4
h
o
u
r
s
 
l
o
n
g
e
r
 
i
n
 
e
l
d
e
r
l
y
 
f
e
m
a
l
e
s
.
 
 
P
o
p
u
l
a
t
i
o
n
 
p
h
a
r
m
a
c
o
k
i
n
e
t
i
c
 
a
n
a
l
y
s
e
s
 
s
u
g
g
e
s
t
 
t
h
a
t
 
t
h
e
 
t
y
p
i
c
a
l
 
v
a
l
u
e
s
 
f
o
r
 
c
l
e
a
r
a
n
c
e
 
d
e
c
r
e
a
s
e
 
b
y
 
 
 
a
p
p
r
o
x
i
m
a
t
e
l
y
 
1
%
 
f
o
r
 
e
a
c
h
 
y
e
a
r
 
o
f
 
a
g
e
 
b
e
t
w
e
e
n
 
2
5
 
a
n
d
 
7
5
 
y
e
a
r
s
 
o
f
 
a
g
e
 
 
A
g
e
 
a
s
 
a
 
p
r
e
d
i
c
t
i
v
e
 
f
a
c
t
o
r
 
o
n
l
y
 
a
c
c
o
u
n
t
s
 
f
o
r
 
a
 
s
m
a
l
l
 
p
e
r
c
e
n
t
a
g
e
 
o
f
 
b
e
t
w
e
e
n
-
p
a
t
i
e
n
t
 
v
a
r
i
a
b
i
l
i
t
y
 
 
 
D
o
s
a
g
e
 
a
d
j
u
s
t
m
e
n
t
 
b
a
s
e
d
 
o
n
 
t
h
e
 
a
g
e
 
o
f
 
t
h
e
 
p
a
t
i
e
n
t
 
i
s
 
n
o
t
 
n
e
c
e
s
s
a
r
y
 
P
e
d
i
a
t
r
i
c
s
 
S
a
f
e
t
y
 
a
n
d
 
e
f
ﬁ
 
c
a
c
y
 
i
n
 
p
e
d
i
a
t
r
i
c
 
p
a
t
i
e
n
t
s
 
h
a
v
e
 
n
o
t
 
b
e
e
n
 
e
s
t
a
b
l
i
s
h
e
d
 
G
e
n
d
e
r
 
H
a
l
f
-
l
i
f
e
 
i
s
 
s
i
m
i
l
a
r
 
i
n
 
m
e
n
 
a
n
d
 
w
o
m
e
n
 
 
A
d
v
e
r
s
e
 
e
v
e
n
t
s
 
s
e
e
n
 
i
n
 
m
e
n
 
a
n
d
 
w
o
m
e
n
 
w
e
r
e
 
g
e
n
e
r
a
l
l
y
 
s
i
m
i
l
a
r
 
e
x
c
e
p
t
 
f
o
r
 
e
f
f
e
c
t
s
 
o
n
 
s
e
x
u
a
l
 
f
u
n
c
t
i
o
n
 
 
D
o
s
a
g
e
 
a
d
j
u
s
t
m
e
n
t
 
b
a
s
e
d
 
o
n
 
g
e
n
d
e
r
 
i
s
 
n
o
t
 
n
e
c
e
s
s
a
r
y
(
c
o
n
t
i
n
u
e
d
)Neuropsychiatric Disease and Treatment 2007:3(2) 198
Goldstein
S
p
e
c
i
a
l
 
p
o
p
u
l
a
t
i
o
n
s
 
R
a
c
e
 
N
o
 
s
p
e
c
i
ﬁ
 
c
 
p
h
a
r
m
a
c
o
k
i
n
e
t
i
c
 
s
t
u
d
y
 
w
a
s
 
c
o
n
d
u
c
t
e
d
 
t
o
 
i
n
v
e
s
t
i
g
a
t
e
 
t
h
e
 
e
f
f
e
c
t
s
 
o
f
 
r
a
c
e
 
P
r
e
g
n
a
n
c
y
 
P
r
e
g
n
a
n
c
y
 
C
a
t
e
g
o
r
y
 
C
 
 
N
e
o
n
a
t
e
s
 
e
x
p
o
s
e
d
 
t
o
 
S
S
R
I
s
 
o
r
 
S
N
R
I
s
,
 
l
a
t
e
 
i
n
 
t
h
e
 
t
h
i
r
d
 
t
r
i
m
e
s
t
e
r
,
 
h
a
v
e
 
d
e
v
e
l
o
p
e
d
 
c
o
m
p
l
i
c
a
t
i
o
n
s
 
 
 
r
e
q
u
i
r
i
n
g
 
p
r
o
l
o
n
g
e
d
 
h
o
s
p
i
t
a
l
i
z
a
t
i
o
n
,
 
r
e
s
p
i
r
a
t
o
r
y
 
s
u
p
p
o
r
t
,
 
a
n
d
 
t
u
b
e
 
f
e
e
d
i
n
g
 
L
i
v
e
r
 
 
D
u
l
o
x
e
t
i
n
e
 
s
h
o
u
l
d
 
n
o
t
 
b
e
 
a
d
m
i
n
i
s
t
e
r
e
d
 
t
o
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
a
n
y
 
h
e
p
a
t
i
c
 
i
n
s
u
f
ﬁ
 
c
i
e
n
c
y
 
 
i
m
p
a
i
r
m
e
n
t
 
(
S
u
r
i
 
e
t
 
a
l
 
2
0
0
5
)
 
P
a
t
i
e
n
t
s
 
w
i
t
h
 
c
l
i
n
i
c
a
l
l
y
 
e
v
i
d
e
n
t
 
h
e
p
a
t
i
c
 
i
n
s
u
f
ﬁ
 
c
i
e
n
c
y
 
h
a
v
e
 
d
e
c
r
e
a
s
e
d
 
C
y
m
b
a
l
t
a
 
m
e
t
a
b
o
l
i
s
m
 
a
n
d
 
 
 
e
l
i
m
i
n
a
t
i
o
n
.
 
M
a
r
k
e
d
l
y
 
i
n
c
r
e
a
s
e
d
 
A
U
C
 
a
n
d
 
T
1
/
2
 
a
f
t
e
r
 
a
 
s
i
n
g
l
e
 
2
0
 
m
g
 
d
o
s
e
 
i
n
 
6
 
c
i
r
r
h
o
t
i
c
 
p
a
t
i
e
n
t
s
 
 
 
(
C
h
i
l
d
-
P
u
g
h
 
C
l
a
s
s
 
B
)
,
 
m
e
a
n
 
p
l
a
s
m
a
 
c
l
e
a
r
a
n
c
e
 
w
a
s
 
a
b
o
u
t
 
1
5
%
 
t
h
a
t
 
o
f
 
a
g
e
-
 
a
n
d
 
g
e
n
d
e
r
-
m
a
t
c
h
e
d
 
 
 
h
e
a
l
t
h
y
 
s
u
b
j
e
c
t
s
,
 
w
i
t
h
 
a
 
5
-
f
o
l
d
 
i
n
c
r
e
a
s
e
 
i
n
 
m
e
a
n
 
e
x
p
o
s
u
r
e
 
(
A
U
C
)
.
 
 
A
l
t
h
o
u
g
h
 
C
m
a
x
 
w
a
s
 
s
i
m
i
l
a
r
 
t
o
 
 
 
n
o
r
m
a
l
s
 
i
n
 
t
h
e
 
c
i
r
r
h
o
t
i
c
 
p
a
t
i
e
n
t
s
,
 
t
h
e
 
h
a
l
f
-
l
i
f
e
 
w
a
s
 
a
b
o
u
t
 
3
 
t
i
m
e
s
 
l
o
n
g
e
r
 
 
R
e
n
a
l
 
 
I
n
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
e
n
d
-
s
t
a
g
e
 
r
e
n
a
l
 
d
i
s
e
a
s
e
 
(
E
S
R
D
)
 
o
r
 
s
e
v
e
r
e
 
r
e
n
a
l
 
i
m
p
a
i
r
m
e
n
t
 
 
i
m
p
a
i
r
m
e
n
t
 
(
c
r
e
a
t
i
n
i
n
e
 
c
l
e
a
r
a
n
c
e
 
<
 
3
0
 
m
L
/
m
i
n
)
 
d
u
l
o
x
e
t
i
n
e
 
i
s
 
n
o
t
 
r
e
c
o
m
m
e
n
d
e
d
 
 
D
u
l
o
x
e
t
i
n
e
 
C
m
a
x
 
a
n
d
 
A
U
C
 
v
a
l
u
e
s
 
w
e
r
e
 
a
p
p
r
o
x
i
m
a
t
e
l
y
 
1
0
0
%
 
g
r
e
a
t
e
r
 
i
n
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
E
S
R
D
 
 
 
r
e
c
e
i
v
i
n
g
 
c
h
r
o
n
i
c
 
i
n
t
e
r
m
i
t
t
e
n
t
 
h
e
m
o
d
i
a
l
y
s
i
s
,
 
b
u
t
 
e
l
i
m
i
n
a
t
i
o
n
 
h
a
l
f
-
l
i
f
e
 
w
a
s
 
s
i
m
i
l
a
r
 
t
o
 
n
o
r
m
a
l
 
 
 
c
o
n
t
r
o
l
s
 
 
 
C
l
i
n
i
c
a
l
 
p
h
a
r
m
a
c
o
l
o
g
y
 
s
t
u
d
i
e
s
 
h
a
v
e
 
n
o
t
 
b
e
e
n
 
c
o
n
d
u
c
t
e
d
 
i
n
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
a
 
m
o
d
e
r
a
t
e
 
d
e
g
r
e
e
 
 
 
o
f
 
r
e
n
a
l
 
d
y
s
f
u
n
c
t
i
o
n
,
 
b
u
t
 
p
o
p
u
l
a
t
i
o
n
 
P
K
 
a
n
a
l
y
s
e
s
 
s
u
g
g
e
s
t
 
t
h
a
t
 
m
i
l
d
 
r
e
n
a
l
 
d
y
s
f
u
n
c
t
i
o
n
 
e
s
t
i
m
a
t
e
d
 
 
 
C
r
C
l
 
3
0
–
8
0
 
m
L
/
m
i
n
)
 
h
a
s
 
n
o
 
s
i
g
n
i
ﬁ
 
c
a
n
t
 
e
f
f
e
c
t
 
o
n
 
d
u
l
o
x
e
t
i
n
e
 
a
p
p
a
r
e
n
t
 
c
l
e
a
r
a
n
c
e
 
O
t
h
e
r
 
S
u
s
t
a
i
n
e
d
 
 
 
I
n
 
c
l
i
n
i
c
a
l
 
t
r
i
a
l
s
,
 
d
u
l
o
x
e
t
i
n
e
 
t
r
e
a
t
m
e
n
t
 
w
a
s
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
m
e
a
n
 
i
n
c
r
e
a
s
e
s
 
i
n
 
b
l
o
o
d
 
p
r
e
s
s
u
r
e
,
 
 
h
y
p
e
r
t
e
n
s
i
o
n
 
a
v
e
r
a
g
i
n
g
 
2
 
m
m
H
g
 
s
y
s
t
o
l
i
c
 
a
n
d
 
0
.
5
 
m
m
H
g
 
d
i
a
s
t
o
l
i
c
 
a
n
d
 
a
n
 
i
n
c
r
e
a
s
e
 
i
n
 
t
h
e
 
i
n
c
i
d
e
n
c
e
 
o
f
 
a
t
 
 
 
l
e
a
s
t
 
o
n
e
 
m
e
a
s
u
r
e
m
e
n
t
 
o
f
 
s
y
s
t
o
l
i
c
 
b
l
o
o
d
 
p
r
e
s
s
u
r
e
 
o
v
e
r
 
1
4
0
 
m
m
H
g
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
p
l
a
c
e
b
o
 
Q
T
c
 
 
N
o
n
e
.
 
I
n
 
t
h
e
 
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
 
s
t
u
d
i
e
s
,
 
d
u
l
o
x
e
t
i
n
e
 
6
0
 
m
g
 
b
i
d
-
t
r
e
a
t
e
d
 
p
a
t
i
e
n
t
s
 
e
x
p
e
r
i
e
n
c
e
d
 
a
 
 
p
r
o
l
o
n
g
a
t
i
o
n
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
s
i
g
n
i
ﬁ
 
c
a
n
t
 
d
e
c
r
e
a
s
e
 
i
n
 
F
r
i
d
e
r
i
c
i
a
’
s
 
c
o
r
r
e
c
t
e
d
 
Q
T
c
 
i
n
t
e
r
v
a
l
 
Q
T
c
F
)
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
 
 
p
l
a
c
e
b
o
-
t
r
e
a
t
e
d
 
p
a
t
i
e
n
t
s
 
-
2
.
8
6
 
m
s
e
c
 
v
s
 
0
.
5
7
 
m
s
e
c
,
 
r
e
s
p
e
c
t
i
v
e
l
y
;
 
p
 
=
 
0
.
0
3
3
.
 
H
o
w
e
v
e
r
,
 
w
h
e
n
 
p
o
o
l
e
d
 
 
 
a
c
r
o
s
s
 
a
l
l
 
d
o
s
e
s
,
 
n
e
i
t
h
e
r
 
t
h
e
 
m
e
a
n
 
c
h
a
n
g
e
 
i
n
 
Q
T
c
F
 
i
n
t
e
r
v
a
l
 
n
o
r
 
i
n
c
i
d
e
n
c
e
 
o
f
 
Q
T
c
F
 
p
r
o
l
o
n
g
a
t
i
o
n
s
 
 
 
a
m
o
n
g
 
d
u
l
o
x
e
t
i
n
e
-
t
r
e
a
t
e
d
 
p
a
t
i
e
n
t
s
 
d
i
f
f
e
r
e
d
 
s
i
g
n
i
ﬁ
 
c
a
n
t
l
y
 
f
r
o
m
 
t
h
e
 
p
l
a
c
e
b
o
 
g
r
o
u
p
 
(
T
h
a
s
e
 
e
t
 
a
l
 
2
0
0
5
)
 
 
L
a
b
o
r
a
t
o
r
y
 
c
h
a
n
g
e
s
 
S
m
a
l
l
 
m
e
a
n
 
i
n
c
r
e
a
s
e
s
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
t
o
 
e
n
d
p
o
i
n
t
 
i
n
 
A
L
T
,
 
A
S
T
,
 
C
P
K
,
 
a
n
d
 
a
l
k
a
l
i
n
e
 
p
h
o
s
p
h
a
t
a
s
e
 
G
l
y
c
e
m
i
c
 
c
o
n
t
r
o
l
 
I
n
 
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
 
s
t
u
d
i
e
s
,
 
m
e
a
n
 
f
r
e
q
u
e
n
c
y
 
o
f
 
s
i
g
n
i
ﬁ
 
c
a
n
t
 
h
y
p
o
g
l
y
c
e
m
i
c
 
e
p
i
s
o
d
e
s
 
w
a
s
 
s
i
g
n
i
ﬁ
 
c
a
n
t
l
y
 
h
i
g
h
e
r
 
 
 
f
o
r
 
t
h
e
 
d
u
l
o
x
e
t
i
n
e
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
t
h
e
 
p
l
a
c
e
b
o
 
g
r
o
u
p
 
(
0
.
0
6
 
e
p
i
s
o
d
e
s
/
w
e
e
k
 
v
s
 
0
.
0
5
 
e
p
i
s
o
d
e
s
/
w
e
e
k
,
 
 
 
r
e
s
p
e
c
t
i
v
e
l
y
)
 
 
 
I
n
 
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
 
s
t
u
d
i
e
s
,
 
t
h
e
 
m
e
a
n
 
i
n
c
r
e
a
s
e
 
i
n
 
f
a
s
t
i
n
g
 
g
l
u
c
o
s
e
 
f
o
r
 
p
l
a
c
e
b
o
-
t
r
e
a
t
e
d
 
p
a
t
i
e
n
t
s
 
w
a
s
 
 
 
0
.
3
5
 
m
m
o
l
/
L
 
(
6
.
3
 
m
g
/
d
L
)
,
 
a
n
d
 
f
o
r
 
d
u
l
o
x
e
t
i
n
e
-
t
r
e
a
t
e
d
 
p
a
t
i
e
n
t
s
 
w
a
s
 
0
.
9
8
 
m
m
o
l
/
L
 
(
1
8
 
m
g
/
d
L
)
;
 
p
 
=
 
0
.
0
2
2
.
 
 
 
A
 
n
o
n
-
s
i
g
n
i
ﬁ
 
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
 
w
a
s
 
o
b
s
e
r
v
e
d
 
b
e
t
w
e
e
n
 
d
u
l
o
x
e
t
i
n
e
 
a
n
d
 
p
l
a
c
e
b
o
,
 
i
n
 
h
e
m
o
g
l
o
b
i
n
 
A
1
c
 
H
b
A
1
c
 
v
a
l
u
e
s
 
 
 
o
b
s
e
r
v
e
d
 
i
n
 
b
o
t
h
 
g
r
o
u
p
s
 
(
d
u
l
o
x
e
t
i
n
e
 
-
0
.
0
3
 
v
s
 
p
l
a
c
e
b
o
 
-
0
.
0
5
)
 
(
E
l
i
 
L
i
l
l
y
 
a
n
d
 
C
o
 
2
0
0
4
)
 
S
m
o
k
i
n
g
 
s
t
a
t
u
s
 
B
i
o
a
v
a
i
l
a
b
i
l
i
t
y
 
(
A
U
C
)
 
i
s
 
a
b
o
u
t
 
o
n
e
-
t
h
i
r
d
 
l
o
w
e
r
 
i
n
 
s
m
o
k
e
r
s
 
t
h
a
n
 
i
n
 
n
o
n
-
s
m
o
k
e
r
s
.
 
 
D
o
s
a
g
e
 
a
d
j
u
s
t
m
e
n
t
 
i
s
 
n
o
t
 
r
e
c
o
m
m
e
n
d
e
d
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
S
N
R
I
,
 
 
s
e
r
o
t
o
n
i
n
-
n
o
r
e
p
i
n
e
p
h
r
i
n
e
 
r
e
u
p
t
a
k
e
 
i
n
h
i
b
i
t
o
r
;
 
S
S
R
I
,
 
s
e
l
e
c
t
i
v
e
 
s
e
r
o
t
o
n
i
n
 
r
e
u
p
t
a
k
e
 
i
n
h
i
b
i
t
o
r
.
T
a
b
l
e
 
2
 
C
o
n
t
i
n
u
e
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T
a
b
l
e
 
3
 
D
u
l
o
x
e
t
i
n
e
 
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
 
m
a
j
o
r
 
d
e
p
r
e
s
s
i
v
e
 
d
i
s
o
r
d
e
r
 
e
f
ﬁ
 
c
a
c
y
 
t
r
i
a
l
s
 
(
c
o
n
t
i
n
u
e
d
)
 
S
t
u
d
y
 
1
 
(
G
o
l
d
s
t
e
i
n
 
e
t
 
a
l
 
2
0
0
2
)
 
S
t
u
d
y
 
2
 
(
M
a
l
l
i
n
c
k
r
o
d
t
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Duloxetine depression
were pooled, the results would likely show that duloxetine 
40 mg bid was superior to placebo at the higher dose and 
that paroxetine was not. Duloxetine would have been 
numerically superior, but not statistically signiﬁ  cantly 
different from paroxetine. Studies 5 and 6 investigated 
an intermediate dose and high dose of duloxetine. The 
intermediate dose of 40 mg bid was the same as that used 
in Studies 3 and 4 so that there would be a common refer-
ence dose for inferring the relationship of the low dose in 
Studies 3 and 4 to the high dose in Studies 5 and 6. Study 5 
showed that both duloxetine doses and the paroxetine dose 
were superior to placebo, but duloxetine and paroxetine 
treatments did not differ statistically. Study 6 showed 
that both doses of duloxetine were superior to placebo, 
but paroxetine was not. If these studies had been pooled, 
both doses of duloxetine would have been signiﬁ  cantly 
superior to placebo, but paroxetine treatment would not. 
Duloxetine would have been numerically superior, but not 
statistically signiﬁ  cantly different from paroxetine.
Studies 7 and 8 (Detke et al 2002a, b) were intended to 
evaluate whether a single 60 mg dose of duloxetine daily would 
be sufﬁ  cient for treatment. Both studies conﬁ  rmed the efﬁ  cacy 
of 60 mg qd. It is valuable to note that the sample sizes were 
higher in these studies, compared with the prior studies, so that 
a smaller effect could be identiﬁ  ed, possibly accounting for the 
highly signiﬁ  cant differences from placebo treatment.
Other duloxetine MDD trials
Additional trials (Table 4) were performed to meet regulatory 
requirements or expand an understanding of the usefulness 
of duloxetine.
Study 9 was an open label safety trial used to increase the 
number of patients treated for 1-year in the regulatory pack-
age. The long-term efﬁ  cacy of duloxetine in elderly patients 
was demonstrated in the subset of patients aged 65 years and 
older (n = 101) who participated in this study (Eli Lilly and Co 
2004). A comparison of visit-wise mean changes in the CGI-S 
score between elderly patients (age 65, n = 101) and those 
patients in the study aged <65 (n = 1178) revealed a somewhat 
more rapid onset of efﬁ  cacy in younger patients; however, at 
subsequent visits, the differences between age groups became 
progressively smaller, and mean changes were essentially 
equal at endpoint (Eli Lilly and Co 2004).
Study 10 (see Table 4) was a relapse-prevention study in 
which all patients received open-label duloxetine (60 mg qd) 
during an initial 12-week acute phase. Acute-phase treatment 
responders were randomized to treatment with either placebo 
or duloxetine 60 mg qd for 26 weeks (continuation phase). 
Duloxetine treatment signiﬁ  cantly delayed relapse.
Study 11 (Table 4) was a switching study. Patients exhib-
iting suboptimal response or poor tolerability to their current 
antidepressant medication, ie, citalopram (40 mg/d), esci-
talopram (20 mg/d), ﬂ  uvoxamine (150 mg/d), paroxetine 
(40 mg/d), sertraline (150 mg/d), or venlafaxine (150 
mg/d) switched directly to duloxetine (60 mg qd) without 
intermediate tapering or titration (“switching group”). The 
other half of the patients initiated treatment with duloxetine 
at either 30 mg qd or 60 mg qd. Duloxetine therapy at 60 mg 
qd showed signiﬁ  cantly greater improvement after 1 week of 
therapy when compared with those initiating therapy at 30 
mg QD. After switching, duloxetine could be titrated up to 
120 mg qd. At the end of the study (12 weeks), the efﬁ  cacy 
was similar for all groups. Using an SSRI or venlafaxine for 
at least 1 week reduced the number of advese events experi-
enced by patients who switched to duloxetine compared with 
the adverse event proﬁ  le experienced by patients who began 
therapy with duloxetine.
Pooled MDD efﬁ  cacy results and subset analyses
MDD efﬁ  cacy in males and females
Data pooled from 7 acute trials preformed in the US showed 
that duloxetine was more effective than placebo in both males 
and females for change in HAMD17, remission, response, 
and quality of life (Kornstein et al 2006). There was no sta-
tistically signiﬁ  cant interaction by gender, indicationg that 
duloxetine efﬁ  cacy is similar for both males and females.
MDD efﬁ  cacy in Hispanic and African-American patients
The efﬁ  cacy of duloxetine did not differ between subsets of 
African-American and Caucasian patients who participated 
in seven double-blind, placebo-controlled studies (Bailey et al 
2006). The efﬁ  cacy of duloxetine in the African-American pa-
tients (as assessed using HAM-D17, CGI-S, and PGI-I scales) 
did not differ signiﬁ  cantly from the efﬁ  cacy observed in the 
Caucasian patients who participated in the seven studies.
Efﬁ  cacy in the treatment of anxious symptoms
of depression
Most patients with MDD have anxious symptoms associated 
with their depression. Effective relief of anxious symptoms 
is an important factor in the successful treatment of 
depression.
Dunner et al (2003) reported the efﬁ  cacy of duloxetine in 
treating depression-associated anxious symptoms in Studies Neuropsychiatric Disease and Treatment 2007:3(2) 202
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Duloxetine depression
1, 4, 7, and 8 using the HAM-D17 anxiety/somatization 
subscale, HAM-D17 Item 10 (anxiety–psychological) and 
the Hamilton Anxiety Rating Scale (HAMA). Duloxetine 
was signiﬁ  cantly more effective than placebo at relieving 
anxious symptoms.
In addition, in Study 5, duloxetine (80 mg/day or 120 
mg/day) signiﬁ  cantly improved both the HAM-D17 anxiety/
somatization subscale and HAMA scale more than placebo 
(Detke et al 2004).
Efﬁ  cacy in patients with melancholic features
A pooled efﬁ  cacy analysis of data from Studies 1–8, dem-
onstrated that the advantage of duloxetine over placebo 
treatment did not differ signiﬁ  cantly between melancholic 
(n = 1278) and non-melancholic patients (n = 635) (Mallinck-
rodt et al 2005). Furthermore, duloxetine was signiﬁ  cantly 
superior to placebo in both melancholic and non-melancholic 
cohorts (p  0.001) for mean change in HAM-D17 total score, 
CGI-S, and PGI-I scales.
Efﬁ  cacy in the treatment of painful physical symptoms 
associated with depression
Visual analogue scales assessing the severity of overall 
pain, headache, back pain, and shoulder pain, and interfer-
ence with daily activities, and amount of time while awake 
were assessed in many of the clinical trials. Studies 4, 7, 
and 8 each showed that some painful symptoms improved 
with duloxetine at 60 mg or 80 mg/d (Goldstein et al 2004a). 
In Studies 7 and 8, duloxetine consistently reduced bodily 
pain severity, as measured by visual analog scales (VAS) 
assessing severity of overall pain, severity of headaches, 
severity of back pain, severity of shoulder pain, interfer-
ence with daily activities, and amount of time in pain while 
awake (Detke et al 2002a, b). Results from the analysis of 
pooled data (Brannan et al 2005; Fava et al 2004) showed 
that duloxetine reduced pain severity by 22%–41% (de-
pending on the item) compared with 5%–18% reduction 
for placebo treatment.
Safety and tolerability
Duloxetine was evaluated in 2418 patients with MDD repre-
senting 1099 patient-years of exposure including 993 patients 
treated for at least 180 days and 445 exposed for at least 
1 year. Among these 2418 patients, 1139 were enrolled in 
Studies 1–8 and 1279 patients were enrolled in Studies 9–11. 
Safety was assessed by adverse events, physical examina-
tions, vital signs, weight, laboratory analyses, and ECGs.
Tolerability proﬁ  le in MDD
In the placebo-controlled database, the incidence of 
serious adverse events for duloxetine-treated patients 
(0.3%, 3/1139) was one-half the rate of placebo-treated 
patients (0.6%, 5/777). In the placebo-controlled data-
base, the incidence of adverse events reported as the 
reason for discontinuation was significantly greater for 
patients receiving duloxetine compared with placebo 
(9.7% vs 4.2%, respectively; p < 0.001 (Tran et al 2003). 
Nausea was the most common adverse event resulting 
in discontinuation of duloxetine therapy (1.4% vs 0.1% 
respectively (Greist et al 2004). The median time to 
onset of nausea among duloxetine-treated patients was 
1 day, while the median duration was 7 days (Greist et 
al 2004). After the first week of therapy, the incidence 
of new cases of nausea was essentially equal to placebo. 
Other adverse events resulting in discontinuation in 
0.5% of duloxetine-treated patients were somnolence, 
dizziness, fatigue, and insomnia. In Study 9, the rate of 
discontinuation due to adverse events was 17.0% in the 
1-year trial at 80–120 mg/day (Raskin et al 2003).
Adverse event proﬁ  le
The stated frequencies of adverse events (AEs) represent the 
proportion of individuals who experienced, at least once, 
a treatment-emergent adverse event of the type listed. An 
event was considered treatment-emergent if it ﬁ  rst occurred 
or worsened after receiving study drug therapy without 
respect to causation.
Treatment-emergent adverse events
The incidences of treatment-emergent AEs that occurred in 
at least 2% of patients treated with Duloxetine, and at a rate 
greater than placebo, are listed in Table 5 (Eli Lilly and Co 
2004). These AEs occurred in patients with MDD treated 
with duloxetine in a dose range of 40–120 mg/d. The most 
commonly observed adverse events in duloxetine-treated 
MDD patients (incidence of 5% or greater and at least twice 
the incidence in placebo patients) were nausea, dry mouth, 
constipation, decreased appetite, fatigue, somnolence, and 
increased sweating.
Headache was commonly reported, but was more 
frequently reported by placebo-treated patients (16.9%) 
than by duloxetine-treated patients (15.0%). Of the pa-
tients that reported nausea with duloxetine, most (94%) 
reported it as mild or moderate in intensity (Greist et al 
2004).Neuropsychiatric Disease and Treatment 2007:3(2) 204
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Discontinuation-emergent events
Following abrupt discontinuation, in MDD placebo-con-
trolled clinical trials of up to 9 weeks’ duration, the following 
symptoms occurred at a rate greater than or equal to 2% and 
at a signiﬁ  cantly higher rate in duloxetine-treated patients 
compared to those discontinuing from placebo: dizziness, 
nausea, headache, paresthesia, vomiting, irritability, and 
nightmare (Eli Lilly and Co 2004). A gradual reduction in 
dose rather than abrupt cessation is recommended.
Effects on male and female sexual function
Because changes in sexual desire, performance, and satisfac-
tion are manifestations of MDD, but can occur with use of 
many antidepressants, these were evaluated by both adverse 
events and the Arizona Sexual Experience Scale (ASEX) 
(McGahuey et al 2000) in Studies 3, 4, 5, and 6 (Delgado 
et al 2005). Based on adverse events, duloxetine-treated males 
had more frequent complaints of abnormal orgasm, ejaculatory 
dysfunction, decreased libido, erectile dysfunction, and delayed 
ejaculation and duloxetine-treated females reported more 
abnormal orgasm and decreased libido. Based on the ASEX, 
duloxetine-treated males had more difﬁ  culty reaching orgasm 
(ASEX Item 4). Duloxetine-treated females did not experience 
more sexual dysfunction on duloxetine than on placebo. Parox-
etine-treated patients had statistically signiﬁ  cantly more sexual 
dysfunction than duloxetine-treated patients (p = 0.015).
Elderly
Clinical studies of duloxetine did not suggest a difference in 
adverse event rates in people over or under 65 years of age 
(Eli Lilly and Co 2004).
Changes in vital signs and ECGs
Cardiovascular effects
Blood pressure and heart rate: Duloxetine treatment, for 
up to 9 weeks in MDD placebo-controlled clinical trials of 
40–120 mg/d doses, caused mean increases in blood pressure, 
averaging 2 mmHg systolic and 0.5 mmHg diastolic and an 
increase in the incidence of at least one measurement of sys-
tolic blood pressure over 140 mmHg compared with placebo. 
Table 5 Treatment-emergent adverse events with frequency of at least 2% for duloxetine treatment and greater frequency for dulox-
etine than placebo in placebo-controlled trials of major depressive disorder (Eli Lilly and Co 2004)
  Placebo (N = 777)   Duloxetine (N = 1139)
  n (%)  n (%)  p value
Nausea   54 (6.9)  227 (19.9)  <0.001
Dry mouth   49 (6.3)  166 (14.6)  <0.001
Constipation   31 (4.0)  130 (11.4)  <0.001
Insomnia   47 (6.0)  113 (9.9)  0.002
Dizziness   37 (4.8)  101 (8.9)  <0.001
Fatigue   29 (3.7)  94 (8.3)  <0.001
Diarrhea   43 5(.5)  88 (7.7)  0.065
Somnolence   21 (2.7)  81 (7.1)  <0.001
Sweating increased  12 (1.5)  70 (6.1)  <0.001
Appetite decreased  15 (1.9)  67 (5.9)  <0.001
Vomiting   20 (2.6)  52 (4.6)  0.027
Vision blurred   10 (1.3)  41 (3.6)  0.002
Tremor   6 (0.8)  31 (2.7)  0.002
Libido decreased  4 (0.5)  29 (2.5)  <0.001
Weight decreased  4 (0.5)  27 (2.4)  0.001
Anorgasmia   0 (0.0)  25 2.2)  <0.001
Hot ﬂ  ashes   6 (0.8)  24 2.1)  0.024
Erectile dysfunctiona  2 (0.8)  16 (4.2)  0.013
Ejaculation delayeda   2 (0.8)  10 (2.6)  0.139
Ejaculation disordera   1 (0.4)  8 (2.1)  0.093
aAdjusted for gender. 
Abbreviations: N, number of patients in the group; n, number of patients who reported the event. Neuropsychiatric Disease and Treatment 2007:3(2) 205
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Blood pressure should be measured prior to initiating treat-
ment and periodically measured throughout treatment (Thase 
et al 2005).
In the placebo-controlled database, the mean change in 
heart rate for duloxetine-treated patients was 1.4 beats per 
minute, while mean changes in systolic and diastolic blood 
pressure were 0.8 mmHg and 0.9 mmHg, respectively (Thase 
et al 2005). At the highest duloxetine dose of 120 mg/d, mean 
increases in systolic and diastolic blood pressure were less 
than 2 mmHg.
In the placebo-controlled database, there was no sig-
niﬁ  cant difference in the incidence of sustained elevation in 
blood pressure (sustained increases of either systolic or dia-
stolic pressures) between patients receiving duloxetine (1.3%, 
14/1116) or placebo (0.8%, 6/757) (Thase et al 2005).
Electrocardiogram changes: Electrocardiograms were 
obtained from 321 duloxetine-treated patients with major 
depressive disorder and 169 placebo-treated patients in 
clinical trials lasting up to 8 weeks. In the placebo-controlled 
database, mean changes in corrected QT intervals did not 
differ signiﬁ  cantly between duloxetine- and placebo-treated 
patients (Thase et al 2005). Duloxetine-treated patients actu-
ally had small decreases in most assessments, including those 
patients receiving doses of 120 mg/d. In addition, the inci-
dence of abnormal ECGs (centrally read and/or investigator 
rated), and the incidence of corrected QT intervals increased 
>30 msec were essentially identical for duloxetine- and 
placebo-treated patients. Thus, duloxetine therapy has not 
been associated with QTc prolongation.
Duloxetine was not associated with the development of 
clinically signiﬁ  cant ECG abnormalities. No clinically signiﬁ  -
cant differences were observed for QT, PR, and QRS intervals 
between duloxetine-treated and placebo-treated patients.
Weight changes
Many antidepressants are associated with weight gain that 
can lead to dissatisfaction with treatment and premature dis-
continuation of therapy. In MDD placebo-controlled clinical 
trials, patients treated with duloxetine for up to 9 weeks 
experienced a mean weight loss of approximately 0.5 kg, 
compared with a mean weight gain of approximately 0.2 kg 
in placebo-treated patients. In diabetic peripheral neuropa-
thy pain (DPNP) placebo-controlled clinical trials, patients 
treated with duloxetine for up to 13 weeks experienced a 
mean weight loss of approximately 1.1 kg, compared with a 
mean weight gain of approximately 0.2 kg in placebo-treated 
patients. In the 12-month open-label study (Study 9) (Eli Lilly 
and Co 2004) patients had a small weight loss early in treat-
ment, returned to baseline weight in succeeding weeks, and 
had a mean weight increase of 2.1 kg (by repeated measures 
analysis) after 52 weeks of treatment.
Laboratory changes
Duloxetine treatment, for up to 13 weeks in placebo-con-
trolled clinical trials, was associated with small mean base-
line to endpoint increases in ALT, AST, CPK, and alkaline 
phosphatase (Eli Lilly and Co 2004). Liver transaminase 
elevations resulted in discontinuation of 0.4% (31/8454) of 
duloxetine-treated patients. In these patients, the median time 
to detection of transaminase elevation was about two months. 
Elevations of ALT to >3 times the upper limit of normal 
occurred in 0.9% (8/930) of duloxetine-treated and 0.3% 
(2/652) of placebo-treated MDD patients. In placebo-con-
trolled studies using a ﬁ  xed dose design, there was evidence 
of a dose-response relationship for ALT and AST elevation 
of >3 times and >5 times the upper limit of normal. Since 
duloxetine and alcohol may interact to cause liver injury, du-
loxetine should not be prescribed to patients with substantial 
alcohol use or evidence of chronic hepatic disease.
Other issues
The duloxetine package label (Anonymous 2006) notes 
other risks that for the most part are similar to most newer 
antidepressants. As with all antidepressants patients should 
be observed closely for clinical worsening and suicidality, 
especially at the beginning of a course of drug therapy, or at 
the time of dose changes.
Although not studied for duloxetine, patients receiving 
a serotonin reuptake inhibitor in combination with a mono-
amine oxidase inhibitor (MAOI) or even starting an MAOI 
shortly after discontinuing an SSRI, have reported of serious, 
sometimes fatal, reactions (eg, hyperthermia, rigidity, myoc-
lonus, autonomic instability with possible rapid ﬂ  uctuations 
of vital signs) and mental status changes, including extreme 
agitation leading to delirium and coma. Therefore, because 
duloxetine inhibits the reuptake of serotonin, duloxetine 
should not be used in combination with an MAOI, within at 
least 14 days of discontinuing treatment with an MAOI, and 
at least 5 days should be allowed after stopping duloxetine 
before starting an MAOI.
If a major depressive episode is the initial presentation 
of bipolar disorder, treatment with an antidepressant alone 
may increase the likelihood of precipitation of a mixed/manic 
episode.Neuropsychiatric Disease and Treatment 2007:3(2) 206
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Since duloxetine has an increased risk of mydriasis, it 
should be used cautiously in patients with controlled nar-
row-angle glaucoma.
Since duloxetine is in a class of drugs known to affect 
urethral resistance, if symptoms of urinary hesitation develop 
during treatment with duloxetine, consideration should be 
given to the possibility that they might be drug related.
Patient perspectives
Depression and antidepressant treatments can impair quality 
of life (Wells et al 1990; Revicki et al 1998). Measuring a 
medication’s impact on quality of life can provide evidence 
of the drug’s broader efﬁ  cacy. Patient-reported outcomes 
measured at baseline and end of trial included the Quality of 
Life in Depression Scale (QLDS) (McKenna 1992), Sheehan 
Disability Scale (SDS) (Sheehan et al 1996), and Patient 
Global Impressions – Improvement (PGI-I).
Quality of life
Four of the placebo-controlled trials (5–8) assessed quality of 
life with the QLDS. Duloxetine produced signiﬁ  cantly superior 
improvement in mean QLDS score, compared with placebo, in 
both studies of duloxetine 60 mg qd (Studies 7 and 8) (Detke et 
al 2000a, b) and at an 80 mg/d dose in Study 6. These ﬁ  ndings 
support duloxetine’s efﬁ  cacy for improving quality of life 
among patients treated for depression.
The SDS was administered in two of the placebo-
controlled studies (Studies 5 and 6). In the acute phase of 
both studies, patients treated with duloxetine (80 mg/d or 
120 mg/d) or paroxetine demonstrated signiﬁ  cantly greater 
improvement on SDS work item, social life item, family life 
item, and SDS total score compared with placebo-treated 
patients (Detke et al 2004; Goldstein et al 2004b).
Somatic symptoms and pain
As noted above, duloxetine has been shown to reduce physi-
cal symptoms associated with depression, particularly painful 
symptoms. As evidence of its independent effect in painful con-
ditions, duloxetine has demonstrated efﬁ  cacy in both diabetic 
peripheral neuropathy pain (Goldstein et al 2005; Raskin et al 
2005) and ﬁ  bromyalgia (Arnold et al 2004, 2005). Therefore, 
treating both the emotional and the painful physical symptoms 
of major depression with duloxetine is associated with improve-
ment in patients’ self-reported quality of life. Patients treated 
with duloxetine also demonstrated consistent improvement 
across trials on the PGI-I in comparison to placebo.
Finally, since duloxetine is an effective antidepressant 
and is also effective for DPNP, it may be that it might be 
particularly useful in patients with both DPNP and depres-
sion; however, this combined use has not been studied.
Dosing and administration
Taking into account the fact that once-daily dosing is ad-
vantageous, especially with regard to ease of use and com-
pliance, duloxetine 60 mg once daily represents the lowest 
dose with consistent and robust efﬁ  cacy. Although 60 mg 
bid demonstrated some numerical advantages over 60 mg 
qd, the higher dose did not show a signiﬁ  cant increase in ef-
ﬁ  cacy but tended to have more frequent adverse events and 
discontinuations. As a consequence, 60 mg is the appropriate 
initial dose for most patients.
Conclusion
Duloxetine demonstrated antidepressant efﬁ  cacy at a dose of 
60 mg qd in two placebo-controlled, randomized, double-blind 
studies. Duloxetine-treated patients had signiﬁ  cant improve-
ment in reducing the symptoms of depression as assessed by 
the HAM-D17, anxious symptoms as measured by the HAM-A, 
and quality of life measures compared with placebo. Dulox-
etine also improved somatic symptoms, particularly painful 
symptoms which may have contributed to signiﬁ  cantly im-
proved remission rates compared with placebo.
Approximately 10% of the 1139 patients with MDD 
in placebo-controlled trials discontinued treatment due to 
an adverse event, compared with 4% of the 777 patients 
receiving placebo. In addition to nausea (1.4% incidence), 
which was the most common reason for discontinuation, 
dizziness, somnolence, and fatigue were the most common 
AEs reported as reasons for discontinuation and all were 
considered drug-related.
The most common AEs experienced by and more com-
monly reported by duloxetine than by placebo-treated patients 
with MDD were nausea, dry mouth, constipation, decreased 
appetite, fatigue, somnolence, and increased sweating. Du-
loxetine treatment lacks effects on ECG, increases heart rate, 
and has little effect on blood pressure or weight.
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